stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Shares outstanding
Novartis AG's shares outstanding at the end of fiscal 2025 was $2.0B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.9B. Over the past ten years it has ranged from $2.0B (fiscal 2025) to $2.4B (fiscal 2015) — the current reading is the lowest in ten years. Novartis AG ranks 8th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.0B | (3.93%) |
| FY2024 | $2.0B | (2.72%) |
| FY2023 | $2.1B | (4.78%) |
| FY2022 | $2.2B | (2.79%) |
| FY2021 | $2.3B | (1.57%) |
| FY2020 | $2.3B | (0.99%) |
| FY2019 | $2.3B | (1.07%) |
| FY2018 | $2.3B | (1.14%) |
| FY2017 | $2.4B | (0.13%) |
| FY2016 | $2.4B | (1.20%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $1.9B | (0.47%) |
| Jun 2026 | $1.9B | (0.10%) |
| Mar 2026 | $1.9B | (1.99%) |
| Dec 2025 | $2.0B | 0.77% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| MRK Merck & Co., Inc. compare | $2.5B |
| JNJ Johnson & Johnson compare | $2.4B |
| NVS Novartis AG | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. compare | $546.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement